Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$11.5MCash on Hand
20.2mo Cash Runway
Follow PLYX by emailGet an email when PLYX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PLYX, unsubscribe in one click. Privacy
📣 What PLYX Says Is Next
fourth quarter of 2026 · “Our most advanced product candidate, PLX-200, targets several LSDs and we intend to launch SOTERIA, a Phase 2 basket trial, to evaluate PLX-200’s safety and efficacy in the fourth quarter of 2026.”
Company press release, Sep 1, 2026 · SEC filing
fourth quarter of 2026 · “Polaryx received a safe to proceed letter in October 2025 from the FDA and plans to initiate SOTERIA in the fourth quarter of 2026 with trial sites in the United States followed by other foreign jurisdictions.”
Company press release, Sep 1, 2026 · SEC filing
Q4 2026 · ““With SOTERIA on track to initiate in Q4 2026, his proven track record will be highly valuable as we execute the trial, advance of key clinical milestones, and deepen our engagement with the patients and families affected by lysosomal storage disorders.” Earlier in his career, Dr. Charlton spent over a decade in clinical practice as a board-certified pediatric endocrinologist.”
Company press release, Sep 1, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Sep 14, 2026 ·
Shareholder vote Shareholders elected Alex Yang and Mitchel Berger as Class I directors, each serving until the 2029 annual meeting. Stockholders also ratified Grant Thorton LLP as independent registered public accounting firm for fiscal 2026, with 30,510,106 votes for and 34,973 against. Form 8-K · SEC filing
Sep 1, 2026 ·
Leadership Polaryx Therapeutics appointed Will Charlton, M.D., M.A.S., as Chief Medical Officer, effective September 1, 2026. He previously served as SVP Clinical Development at Tyra Biosciences and as CMO at Spruce Biosciences, and will lead the planned SOTERIA Phase 2 trial, slated to start in Q4 2026. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2028 · Phase 2 · Upcoming Trial · Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol) Registry primary completion date, not a results date
📊 Drug Pipeline
Drug
Indication
Most advanced trial
Status
Also used in these trials (approved or third-party drugs, not PLYX's own candidates): Gemfibrozil.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
PLYX holds $11.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.7M/quarter from operations,
an estimated runway of 20.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:31 · Moderate
Cash runway 20 months +8
S-1 registration (Nov 2025) +8
Going-concern doubt in the latest 10-Q +15These matters, along with the conditions described above, raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the date these financial statements were available to be issued.10-Q, Nov 2026
Share count 49,845,993 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full PLYX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PLYX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.